Advertisement

 

 

Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.

Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.
Author Information (click to view)

Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, Liang S, Shepard C, Wang L, Wang A, Zhang F, Kourtis AP,


Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, Liang S, Shepard C, Wang L, Wang A, Zhang F, Kourtis AP, (click to view)

Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, Liang S, Shepard C, Wang L, Wang A, Zhang F, Kourtis AP,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

The Journal of infectious diseases 2016 9 22() pii

Abstract
BACKGROUND
 There is limited information on HBV-antiviral therapy among HIV/HBV co-infected pregnant women.

METHODS
 Phase II randomized controlled trial of a regimen containing tenofovir (TDF) /lamivudine (3TC), versus 3TC, in HIV/HBV co-infected pregnant women in China. The HBV virological response was compared in study arms (Clinical Trials registration: #NCT01125696).

RESULTS
 Median decline of HBV DNA was 2.60 log10 copies/ml in the TDF-3TC arm; 2.24 log10 copies/ml in the 3TC arm (p=0.41). All women achieved delivery HBV DNA levels <6 log10 copies/ml. CONCLUSIONS
 Initiation of either regimen led to achieving HBV DNA levels below the threshold associated with perinatal HBV transmission.

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × 3 =

[ HIDE/SHOW ]